» Articles » PMID: 23498720

Role of MYCN in Retinoblastoma

Overview
Journal Lancet Oncol
Specialty Oncology
Date 2013 Mar 19
PMID 23498720
Citations 10
Authors
Affiliations
Soon will be listed here.
Citing Articles

Regulates Cell-Cell Adhesion and EMT and Inhibits Retinoblastoma Progression.

Hopkins J, Asada K, Leung A, Papadaki V, Davaapil H, Morrison M Cancers (Basel). 2022; 14(19).

PMID: 36230849 PMC: 9563430. DOI: 10.3390/cancers14194926.


Bioinformatics analysis of multi-omics data identifying molecular biomarker candidates and epigenetically regulatory targets associated with retinoblastoma.

Zeng Y, He T, Liu J, Li Z, Xie F, Chen C Medicine (Baltimore). 2020; 99(47):e23314.

PMID: 33217867 PMC: 7676602. DOI: 10.1097/MD.0000000000023314.


Cell-free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience.

Kothari P, Marass F, Yang J, Stewart C, Stephens D, Patel J Cancer Med. 2020; 9(17):6093-6101.

PMID: 32633890 PMC: 7476838. DOI: 10.1002/cam4.3144.


LncRNA CANT1 suppresses retinoblastoma progression by repellinghistone methyltransferase in PI3Kγ promoter.

Ni H, Chai P, Yu J, Xing Y, Wang S, Fan J Cell Death Dis. 2020; 11(5):306.

PMID: 32366932 PMC: 7198571. DOI: 10.1038/s41419-020-2524-y.


Dynamic chromosomal tuning of a novel GAU1 lncing driver at chr12p13.32 accelerates tumorigenesis.

Chai P, Jia R, Jia R, Pan H, Wang S, Ni H Nucleic Acids Res. 2018; 46(12):6041-6056.

PMID: 29741668 PMC: 6158754. DOI: 10.1093/nar/gky366.